Patents by Inventor Amanda E. I. Proudfoot

Amanda E. I. Proudfoot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 11773159
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 3, 2023
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20220195031
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 23, 2022
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20210130452
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: September 29, 2020
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same
    Patent number: 10829552
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20190100584
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 4, 2019
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same
    Patent number: 10017568
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E. I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL17-A/F AND POLYPEPTIDES COMPRISING THE SAME
    Publication number: 20140314743
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: May 4, 2012
    Publication date: October 23, 2014
    Applicant: Merck Patent GmbH
    Inventors: Heidi Rommelaere, Joost Alexander Kolkman, Michael John Scott Saunders, Ann Union, Yolande Chvatchko, Amanda E.I. Proudfoot, Alain Vicari, Denis Bruniquel, Laurent Chevalet, Olivier Leger
  • Method of treatment with a RANTES antagonist polypeptide
    Patent number: 6555105
    Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1&agr; antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1&agr;.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 29, 2003
    Assignee: Glaxo Group Limited
    Inventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
  • DNA encoding rantes peptide fragments and methods of treatment with the fragments
    Patent number: 6159711
    Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1.alpha. antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1.alpha..
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: December 12, 2000
    Assignee: Glaxo Group Limited
    Inventors: Amanda E. I. Proudfoot, Timothy N. C. Wells